-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $23

Benzinga·11/11/2025 14:32:49
Listen to the news
Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and lowers the price target from $26 to $23.